Who is sponsoring NCT05544227?

NCT05544227 is sponsored by Williams Cancer Foundation.

What drugs are being tested in NCT05544227?

Interventions in NCT05544227: SV-102.

What condition does NCT05544227 study?

NCT05544227 studies Metastatic Castration-resistant Prostate Cancer.

Is NCT05544227 still recruiting?

NCT05544227 is currently completed. Last updated 23 July 2025.

Last reviewed 2025-07-23 · How we verify

NCT05544227

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase 1 Trial of SYNC-T - Immunotherapy for Advanced/Metastatic Castration-Resistant Prostate Cancer

Completed Phase 1 Last updated 23 July 2025

What this trial tests

Phase 1 trial testing SV-102 in Metastatic Castration-resistant Prostate Cancer in 15 participants. Completed in 1 June 2025.

Timeline

1 February 2023

Primary endpoint
10 December 2024

1 June 2025

Quick facts

Lead sponsor	Williams Cancer Foundation
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	15
Start date	1 February 2023
Primary completion	10 December 2024
Estimated completion	1 June 2025
Sites	1 location across Mexico

Drugs / interventions tested

SV-102 — full drug profile →

Conditions studied

Metastatic Castration-resistant Prostate Cancer — all drugs for Metastatic Castration-resistant Prostate Cancer →

Sponsor

Williams Cancer Foundation

Who can join

18 and older, male only, with Metastatic Castration-resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

SV-102 is intended to overcome the complex and multifactorial nature of the mechanisms mediating tumor immune evasion, by the use of a combination of therapeutic agents that elicit multiple immuno-pharmacologic effects.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy for Prostate Cancer: A Current Systematic Review and Patient Centric Perspectives.
Rehman LU, Nisar MH, Fatima W, Sarfraz A, et al · · 2023 · cited 21× · PMID 36835981 · DOI 10.3390/jcm12041446
Current status and future directions of nanovaccine for cancer: a bibliometric analysis during 2004-2023.
Hou Y, Li Y, Zhang Y, Zhang J, et al · · 2024 · cited 7× · PMID 39136021 · DOI 10.3389/fimmu.2024.1423212

Verify or expand the search:

Other trials of SV-102

Trials testing the same drug.

NCT06533644 — A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer · Phase 2 · recruiting

Other recruiting trials for Metastatic Castration-resistant Prostate Cancer

Currently open trials in the same condition.

NCT07142551 — Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response · Phase 2 · recruiting
NCT07288359 — Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and · Phase 1, PHASE2 · recruiting
NCT07244341 — A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer ( · Phase 1 · recruiting
NCT07213674 — A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic · Phase 3 · recruiting
NCT07189403 — A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resist · Phase 1 · recruiting

Other Williams Cancer Foundation trials

Trials by the same sponsor.

NCT05544240 — Phase 1 Trial of SYNC-T - Immunotherapy for Patients With Advanced/Metastatic Solid Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05544227 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Williams Cancer Foundation
Last refreshed: 23 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05544227.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing